The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survival

British Journal of Cancer

Volumn 94, Issue 10, 2006, Pages 1412-1419

  Evans, C ^a   Morrison, I ^a   Heriot, A G ^a   Bartlett, J B ^a   Finlayson, C ^a   Dalgleish, A G ^a   Kumar, D ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Colorectal cancer; Cytokines; Immune suppression; Proliferation: apoptosis; Survival

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; KI 67 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD CULTURE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; TUMOR IMMUNITY;

ADENOCARCINOMA; AGED; APOPTOSIS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYTOKINES; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; KI-67 ANTIGEN; MALE; NEOPLASM INVASIVENESS; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646849272     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603104     Document Type: Article

References (35)

1. Aotake T, Lu CD, Chiba Y, Muraoka R, Tanigawa N (1999) Changes of angiogenesis and tumor cell apoptosis during colorectal carcinogenesis. Clin Cancer Res 5: 135-142
2. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357: 539-545
3. Berghella AM, Pellegrini P, Del Beato T, Maccarone D, Adorno D, Casciani CU (1996) Prognostic significance of immunological evaluation in colorectal cancer. Cancer Biother Radiopharm 11: 355-361
4. Cancer Research UK (2005) Cancer stats - bowel (colorectal) cancer. www.cancerresearchuk.org
5. Ding YH, Fu S, Zamarin D, Bromberg J (2003) Interleukin-10. In The cytokine Handbook, 2 Volume Set, 4th Edition, Thompson AW, Lotze MT (eds) London, Academic Press, pp 603-625. Elsevier Science
6. Erdman SE, Rao VP, Poutahidis T, Ihrig MM, Ge Z, Feng Y, Tomczak M, Rogers AB, Horwitz BH, Fox JG (2003) CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res 63: 6042-6050
7. Fodde R, Smits R, Clevers H (2001) APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 1: 55-67
8. Funk JO (1999) Cancer cell cycle control. Anticancer Res 19: 4772-4780
9. Galizia G, Lieto E, De Vita F, Romano C, Orditura M, Castellano P, Imperatore V, Infusino S, Catalano G, Pignatelli C (2002) Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome. J Interferon Cytokine Res 22: 473-482
10. Garrido F, Algarra I (2001) MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 83: 117-158
11. Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG (2000) Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer 82: 1009-1012
12. Higaki S, Akazawa A, Nakamura H, Yanai H, Yoshida T, Okita K (1999) Metaplastic polyp of the colon develops in response to inflammation. J Gastroenterol Hepatol 14: 709-714
13. Itzkowitz SH, Yio X (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287: G7-17
14. Jacobson-Brown P, Neuman MG (2004) Colorectal polyposis and immune-based therapies. Can J Gastroenterol 18: 239-249
15. Kidd P (2003) Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 8: 223-246
16. Koornstra JJ, de Jong S, Hollema H, de Vries EG, Kleibeuker JH (2003) Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature. Crit Rev Oncol Hematol 45: 37-53
17. Koornstra JJ, Rijcken FE, de Jong S, Hollema H, de Vries EG, Kleibeuker JH (2004) Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas. Histopathology 44: 9-17
18. Leslie A, Carey FA, Pratt NR, Steele RJ (2002) The colorectal adenoma-carcinoma sequence. Br J Surg 89: 845-860
19. Macarthur M, Hold GL, El Omar EM (2004) Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 286: G515-G520
20. Matsuda M, Salazar F, Petersson M, Masucci G, Hansson J, Pisa P, Zhang QJ, Masucci MG, Kiessling R (1994) Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 180: 2371-2376
21. Nagorsen D, Scheibenbogen C, Letsch A, Germer CT, Buhr HJ, Hegewisch-Becker S, Rivoltini L, Thiel E, Keilholz U (2005) T cell responses against tumor associated antigens and prognosis in colorectal cancer patients. J Transl Med 3: 3
22. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58: 3491-3494
23. Nakamori M, Iwahashi M, Nakamura M, Ueda K, Zhang X, Yamaue H (2003) Intensification of antitumor effect by T helper 1-dominant adoptive immunogene therapy for advanced orthotopic colon cancer. Clin Cancer Res 9: 2357-2365
24. Nakayama H, Kitayama J, Muto T, Nagawa H (2000) Characterization of intracellular cytokine profile of CD4(+) T cells in peripheral blood and tumor-draining lymph nodes of patients with gastrointestinal cancer. Jpn J Clin Oncol 30: 301-305
25. O'Byrne KJ, Dalgleish AG (2001) Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 85: 473-483
26. O'Hara RJ, Greenman J, MacDonald AW, Gaskell KM, Topping KP, Duthie GS, Kerin MJ, Lee PW, Monson JR (1998) Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production. Clin Cancer Res 4: 1943-1948
27. Robinson SC, Coussens LM (2005) Soluble mediators of inflammation during tumor development. Adv Cancer Res 93: 159-187
28. Salminen E, Palmu S, Vahlberg T, Roberts PJ, Soderstrom KO (2005) Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer. World J Gastroenterol 11: 3245-3249
29. Shibata M, Nezu T, Kanou H, Abe H, Takekawa M, Fukuzawa M (2002) Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J Clin Gastroenterol 34: 416-420
30. Sveinbjornsson B, Rushfeldt C, Olsen R, Smedsrod B, Seljelid R (1997) Cytotoxic effect of cytokines on murine colon carcinoma cells involves TNF-mediated apoptosis. Biochem Biophys Res Commun 233: 270-275
31. Terabe M, Park JM, Berzofsky JA (2004) Role of IL-13 in regulation of antitumor immunity and tumor growth. Cancer Immunol Immunother 53: 79-85
32. Tomita K, Okabe S (2005) Exogenous histamine stimulates colorectal cancer implant growth via immunosuppression in mice. J Pharmacol Sci 97: 116-123
33. Valera V, Yokoyama N, Walter B, Okamoto H, Suda T, Hatakeyama K (2005) Clinical significance of Ki-67 proliferation index in disease progression and prognosis of patients with resected colorectal carcinoma. Br J Surg 92: 1002-1007
34. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW (2005) Colorectal cancer. Lancet 365: 153-165
35. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5: 263-274